Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.

Blood - 15 Jun 2007

Modi Hardik, McDonald Tinisha, Chu Su, Yee Jiing-Kuan, Forman Stephen J, Bhatia Ravi

Abstract excerpt

Increased levels of Bcr-Abl expression in chronic myelogenous leukemia (CML) cells are associated with disease progression and imatinib (IM) resistance. However, it is not clear if these associations are a direct result of elevated Bcr-Abl expression. We used a human transduction model of CML to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Cell Line, Transformed
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cells

Share to Imatinib Mesylate

Share to Piperazines

Share to Pyrimidines

Share to Transduction, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 17347407
DOI: 10.1182/blood-2006-06-032490
PMCID: PMC1890842

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-17347407-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.PMID 17347407Read ↗

Bcr-Abl Expression Levels Determine the Rate of Development of Resistance to Imatinib Mesylate in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fateSemantic proximity Read ↗

Consequences of BCR‐ABL Expression within the Hematopoietic Stem Cell in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinibSemantic proximity Read ↗

Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.Semantic proximity Read ↗

Targeting primary human leukaemia cells with RNA interference: Bcr‐Abl targeting inhibits myeloid progenitor self‐renewal in chronic myeloid leukaemia cellsSemantic proximity Read ↗

Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylateSemantic proximity Read ↗

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.Semantic proximity Read ↗

Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABLSemantic proximity Read ↗

Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)Semantic proximity Read ↗

Specific inhibition of bcr-abl gene expression by small interfering RNASemantic proximity Read ↗

The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.